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b Department of Visceral-, Thoracic- and Vascular Surgery, University Hospital Marburg, Marburg, GermanyIn this issue of EBioMedicine, Pandharipande and colleagues report but at the same time represent a danger due to the inherent complica-
important data that may well assist the decision-making process
when screening families at risk for pancreatic ductal adenocarcinoma
(PDAC) (Pandharipande et al., 2015). The aim of the study was to com-
pare, using a simulation model, the effectiveness of different screening
strategies in BRCA2-mutation carriers.
Hereditary factors play a role in the development of PDAC in about
5% of all cases (Bartsch et al., 2012). Individuals at increased risk of de-
veloping PDAC can be subdivided into those with an underlying gene
defect such as CDKN2A, BRCA1/2, PALB2 and STK11-mutations and
those individuals with a signiﬁcant family history of PDAC (Familial
pancreatic cancer (FPC)). Carriers of a BRCA2 mutation constitute the
largest group of mutation carriers at risk for PDAC. The risk of develop-
ing PDAC in this group is between 5–10%, depending on the number of
patients with PDAC in the family (van Asperen et al., 2005).
The prognosis of patients with PDAC has notmeaningfully improved
over the recent decades and it is now clear that the onlyway to improve
matters will be through detection of early stage PDAC, or even better its
precursor lesions (IPMN or PanIN3). Interest in screening individuals at
risk for PDAC has also increased over the last decade.
An international consortium of experts recently recommended that
screening should be considered in individuals with a N5% lifetime risk
of PDAC (Canto et al., 2013). However, studies published so far (mostly
on FPC) have produced rather disappointing outcomes. Besides the very
low screening yield (PDAC in 1–2%), the majority of screen-detected
cancers proved to be advanced tumors. A small proportion of patients
underwent surgery for precursor lesions, but only a few had high-risk
precursor lesions (PanIN3 or high-grade IPMN) (Bartsch et al., 2012).
A major problem that must be confronted when screening individ-
uals at high-risk of PDAC is the potential morbidity (up to 40%) (Keck
et al., 2015; Diener et al., 2011) and mortality (0.5–6%) associated
with the surgical treatment of suspicious lesions (Keck et al., 2015;
Diener et al., 2011), even in specialized centers. Due to a lack of preop-
erative certainty in many cases as to the nature of the lesion (low or
high-risk precursor lesion or cancer), theoretically a patient could die
following surgery for a benign, low-risk lesion. Screeningmay therefore
facilitate both the detection of early cancer and an improved prognosis,DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.11.005.
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in surveillance programmust therefore be a priority.
In the absence of long-term clinical studies, the study by
Pandharipande and colleagues provides important information on the
effectiveness of screening in relation to the risk of developing PDAC in
BRCA2mutation carriers (Pandharipande et al., 2015). The authors de-
veloped a simulation screening model based on MRI-scanning for fam-
ilies with a BRCA2 mutation. All available data on cancer risks in
mutation carriers, and SEER data on PDAC were used to develop the
model. The authors then calculated the expected gain in life expectancy
(LE) for different phenotypes and different surveillance protocols, com-
pared to no screening. Furthermore, in the sensitivity analysis they eval-
uated additional screening strategies, screening intervals and surgical
mortality.
They found that one-time screening of the primary BRCA2 cohort at
age 50 resulted in small LE gains (a few days). Annual screening from
age 50 was most effective for BRCA2 mutation carriers with two ﬁrst-
degree relative (FDR) with PDAC (LE gain of 20 days), and for those
with three or more FDR with PDAC (260 days) but not for the primary
cohort (reduced LE of 13 days). The authors attributed the reduced life
expectancy in the latter group to frequent screening in low-risk muta-
tion carriers, as false positive ﬁndings and an increased discovery of in-
signiﬁcant lesions represents an increased burden due to the resulting
surgical interventions.
Another important ﬁnding was that the effectiveness of screening
was strongly inﬂuenced by themortality rate associated with the surgi-
cal intervention. The gain of LE of one-time screening disappearedwith a
slight increase of the surgical mortality rate to N2.3%.
A limitation of the studywas that data on PDAC risk are not available
for individuals with both a BRCA2mutation and various numbers of rel-
atives with PDAC.
In conclusion, this study provides important information that could
be helpful in the management of individuals at high-risk for PDAC. Al-
though the results of a simulationmodel study cannot be directly trans-
lated to clinical practice, the present study suggests that surveillance of
BRCA2mutation carriers should probably be restricted to those with the
highest risks, i.e., mutation carriers with two or more FDR with PDAC.
Moreover, surveillance and management of high-risk groups should
only be performed in high-volume expert centers.
Perhaps themost important conclusion is that, before entering a pro-
gram, all individuals should be clearly informed about the advantagesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
1859H.F.A. Vasen, D. Bartsch / EBioMedicine 2 (2015) 1858–1859and disadvantages (and dangers) of surveillance. We also suggest that
similar studies should nowbe performed for other syndromes associated
with an increased risk of PDAC.
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